Precigen Inc. (PGEN)
NASDAQ: PGENHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 2:07 PM ET
PGEN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.70B
- EPS (TTM)
- -$1.04
- Dividend yield
- None
- 52-week range
- 2.99 – 8.98
- Day range
- 7.40 – 7.60
- Volume / Avg
- 1.44M / 5.02M
- Beta
- —
- Shares outstanding
- 358.04M
52-week range
PGEN stock today
Precigen (PGEN) is trading at $7.56 on Oct 8, up 0.20% (+$0.015), versus the S&P 500's 0.68% decline. At this level, PGEN sits in the middle of its 52-week range of $2.99 to $8.98: 15.9% below the high, set on Sep 30, 2026 and 152.7% above the low. PGEN is up 80.4% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 127.8%.
Precigen has posted a net loss over the last twelve months (EPS of -$1.04), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Precigen
Company profilePrecigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Helen Sabzevari MPH, Ph.D.
- Headquarters
- Germantown, MD
- Employees
- 160
- Website
- precigen.com
Financial highlights
Full financialsIn fiscal 2025, Precigen generated $9.7 million in revenue, up 146.7% from fiscal 2024. Precigen reported a net loss of $250.6 million, compared with a loss of $126.2 million a year earlier. Operating margin was -1141.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $9.68M | $3.92M | $6.22M | $26.91M | $14.27M |
| Growth | +146.73% | -36.95% | -76.87% | +88.61% | -55.40% |
| Net income | $-250.64M | $-126.23M | $-95.90M | $28.32M | $-92.17M |
| EPS (diluted) | $-1.37 | $-0.47 | $-0.39 | $0.14 | $-0.47 |
Analyst forecast
ForecastConsensus (4 analysts)
buy
Avg. price target
$13.65+80.68%
- Strong buy 1
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $0.05 vs —
PGEN news
All PGEN news- Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealNasdaqNVS, IONS, ACIU, PGEN
- PGEN Stock Up More Than 50% in 3 Months: Here's What You Should KnowNasdaqPGEN, MRK, INO
- Novo's Denecimig BLA Review Delayed by FDA Facility Remediation WorkNasdaqNVO, ALDX, ACIU, PGEN
- The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health CompaniesNasdaqABT, CORT, BHC, PGEN
- Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in FocusNasdaqICE, FAST, DGX, TMO
- 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate HikeNasdaqABT, CORT, BHC, PGEN
- Here's Why You Should Add URGN Stock to Your Portfolio NowNasdaqURGN, TEVA, ACIU, PGEN
- KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing NearsNasdaqKOD, REGN, ACIU, PGEN
Precigen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZLABZai Lab Limited ADR | 24.41 | -3.58% | $2.74B | vs PGEN |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 7.08 | -4.78% | $2.62B | vs PGEN |
| MBXMBX Biosciences Inc. | 51.79 | -5.05% | $2.49B | vs PGEN |
| LQDALiquidia Corporation | 27.84 | +4.35% | $2.49B | vs PGEN |
| RCUSArcus Biosciences Inc. | 23.34 | -4.81% | $2.94B | vs PGEN |
| ELVNEnliven Therapeutics Inc. | 40.12 | -3.00% | $2.94B | vs PGEN |
| NAMSNewAmsterdam Pharma Company N.V. | 21.08 | -4.74% | $2.46B | vs PGEN |
| SUPNSupernus Pharmaceuticals Inc. | 42.06 | -2.30% | $2.45B | vs PGEN |
Indexes, lists and sector
Precigen stock FAQ
What is Precigen's stock price today?
PGEN last traded at $7.56 as of Oct 8, 2:07 PM EDT, up 0.20% on the day. Prices are delayed at least 15 minutes.
Who is Precigen's CEO?
Dr. Helen Sabzevari MPH, Ph.D. is the chief executive officer of Precigen Inc., which has about 160 employees.
What is the PGEN 52-week high?
The 52-week high for PGEN is $8.98 and the 52-week low is $2.99. The stock is currently 15.9% below its high.